GL1X · GenesisL1 explorer

Research workbench

Allosteric inhibition of glycogen phosphorylase a by a potential antidiabetic drug

Analyse Allosteric inhibition of glycogen phosphorylase a by a potential antidiabetic… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3AMV
Type
protein
Length
812 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Protein (glycogen phosphorylase)
EC
2.4.1.1
UniProt
P00489
Ligands
PLP, BIN, GLC
Pockets
15 · best druggability 0.84

Structure

x-ray diffraction · 1 distinct chain · 53% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProtein (glycogen phosphorylase) (EC 2.4.1.1)protein81253% helix, 15% strandP00489

Ligands and binding sites

  • PLP · Pyridoxal-5'-phosphate · ligand · chains A
  • BIN · 2,3-dicarboxy-4-(2-chloro-phenyl)-1-ethyl-5-isopropoxycarbonyl-6-methyl-pyridinium · ligand · chains A
  • GLC · alpha-D-glucopyranose · sugar · chains A
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

15 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12790.840.9649GLC, PLP
2870.720.9526empty
33740.670.8045empty
41240.540.8219empty
51860.480.7627empty

Modifications

Observed in the structure: 1 cofactor, 1 modified (pyridoxal phosphate Schiff base, phosphorylation).

Compared structures

  • 3AMV · Allosteric inhibition of glycogen phosphorylase a by a potential antidiabetic drug · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.